Young J Juhn1, Hirohito Kita2, Barbara P Yawn3, Thomas G Boyce2, Kwang H Yoo4, Michaela E McGree5, Amy L Weaver5, Peter Wollan3, Robert M Jacobson2. 1. Departments of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minn. Electronic address: juhn.young@mayo.edu. 2. Departments of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minn. 3. Department of Research, Olmsted Medical Center, Rochester, Minn. 4. Departments of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minn; Department of Internal Medicine, Kunkook University School of Medicine, Seoul, South Korea. 5. Department of Health Sciences Research, Mayo Clinic, Rochester, Minn.
Abstract
BACKGROUND: Individuals with asthma have been reported to be at increased risk of invasive pneumococcal disease (IPD). These findings need to be confirmed in a different population-based study setting. OBJECTIVE: We assessed whether serious pneumococcal disease (SPD), defined as an IPD, pneumococcal pneumonia, or both, was associated with asthma status. METHODS: This is a retrospective case-control study using criteria-based methods for ascertaining SPD, as well as asthma. Subjects were residents of Rochester, Minnesota, who had SPD between 1964 and 1983 (the primarily pre-pneumococcal vaccine era) and their age- and sex-matched control subjects using 1:2 matching. Potential cases and control subjects were identified by using the Rochester Epidemiology project database and confirmed by medical record reviews. All cases and control subjects were merged with the database comprising the entire pool of Rochester residents with and without asthma between 1964 and 1983. RESULTS: A total of 3941 records of potential patients with SPD were reviewed, and we identified 174 cases of SPD (51% male subjects and 94% white subjects). SPD was associated with a history of asthma among all ages (odds ratio, 2.4; 95% CI, 0.9-6.6; P = .09) and among adults (odds ratio, 6.7; 95% CI, 1.6-27.3; P = .01), controlling for high-risk conditions for IPD and smoking exposure. The population-attributable risk percentage was 17% in the adult population. CONCLUSION: Adults with asthma might be at increased risk of SPD.
BACKGROUND: Individuals with asthma have been reported to be at increased risk of invasive pneumococcal disease (IPD). These findings need to be confirmed in a different population-based study setting. OBJECTIVE: We assessed whether serious pneumococcal disease (SPD), defined as an IPD, pneumococcal pneumonia, or both, was associated with asthma status. METHODS: This is a retrospective case-control study using criteria-based methods for ascertaining SPD, as well as asthma. Subjects were residents of Rochester, Minnesota, who had SPD between 1964 and 1983 (the primarily pre-pneumococcal vaccine era) and their age- and sex-matched control subjects using 1:2 matching. Potential cases and control subjects were identified by using the Rochester Epidemiology project database and confirmed by medical record reviews. All cases and control subjects were merged with the database comprising the entire pool of Rochester residents with and without asthma between 1964 and 1983. RESULTS: A total of 3941 records of potential patients with SPD were reviewed, and we identified 174 cases of SPD (51% male subjects and 94% white subjects). SPD was associated with a history of asthma among all ages (odds ratio, 2.4; 95% CI, 0.9-6.6; P = .09) and among adults (odds ratio, 6.7; 95% CI, 1.6-27.3; P = .01), controlling for high-risk conditions for IPD and smoking exposure. The population-attributable risk percentage was 17% in the adult population. CONCLUSION: Adults with asthma might be at increased risk of SPD.
Authors: K A Robinson; W Baughman; G Rothrock; N L Barrett; M Pass; C Lexau; B Damaske; K Stefonek; B Barnes; J Patterson; E R Zell; A Schuchat; C G Whitney Journal: JAMA Date: 2001-04-04 Impact factor: 56.272
Authors: J P Nuorti; J C Butler; M M Farley; L H Harrison; A McGeer; M S Kolczak; R F Breiman Journal: N Engl J Med Date: 2000-03-09 Impact factor: 91.245
Authors: Thomas R Talbot; Tina V Hartert; Ed Mitchel; Natasha B Halasa; Patrick G Arbogast; Katherine A Poehling; William Schaffner; Allen S Craig; Marie R Griffin Journal: N Engl J Med Date: 2005-05-19 Impact factor: 91.245
Authors: S Chinn; D Jarvis; P Burney; C Luczynska; U Ackermann-Liebrich; J M Antó; I Cerveri; R De Marco; T Gislason; J Heinrich; C Janson; N Künzli; B Leynaert; F Neukirch; J Schouten; J Sunyer; C Svanes; P Vermeire; M Wjst Journal: Thorax Date: 2004-08 Impact factor: 9.139
Authors: Peter A B Wark; Sebastian L Johnston; Fabio Bucchieri; Robert Powell; Sarah Puddicombe; Vasile Laza-Stanca; Stephen T Holgate; Donna E Davies Journal: J Exp Med Date: 2005-03-21 Impact factor: 14.307
Authors: Amy S Feldman; Yuan He; Martin L Moore; Marc B Hershenson; Tina V Hartert Journal: Am J Respir Crit Care Med Date: 2015-01-01 Impact factor: 21.405
Authors: T Jartti; S Kuneinen; P Lehtinen; V Peltola; T Vuorinen; M Leinonen; O Ruuskanen Journal: Eur J Clin Microbiol Infect Dis Date: 2010-10-13 Impact factor: 3.267
Authors: Michelle L Hernandez; Margaret Herbst; John C Lay; Neil E Alexis; Willie June Brickey; Jenny P Y Ting; Haibo Zhou; David B Peden Journal: J Allergy Clin Immunol Date: 2012-07-04 Impact factor: 10.793
Authors: Carlos F Santillan Salas; Sonia Mehra; Maria R Pardo Crespo; Young J Juhn Journal: Allergy Asthma Proc Date: 2013 Sep-Oct Impact factor: 2.587
Authors: Bong-Seong Kim; Sonia Mehra; Barbara Yawn; Charles Grose; Robert Tarrell; Brian Lahr; Young J Juhn Journal: J Pediatr Date: 2013-04-13 Impact factor: 4.406